Ann Hematol (2016) 95:1559–1560
DOI 10.1007/s00277-016-2739-2

LETTER TO THE EDITOR

Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms

Luisa Anelli[1] · Antonella Zagaria[1] · Nicoletta Coccaro[1] · Giuseppina Tota[1] · Angela Minervini[1] · Paola Casieri[1] · Luciana Impera[1] · Crescenzio Francesco Minervini[1] · Claudia Brunetti[1] · Alessandra Ricco[1] · Paola Orsini[1] · Cosimo Cumbo[1] · Giorgina Specchia[1] · Francesco Albano[1]

Received: 26 April 2016 / Accepted: 16 June 2016 / Published online: 1 July 2016

Dear Editor,

Calreticulin (*CALR*) gene mutations (*CALR*^{mut}) have recently been discovered in about 20–35 % of patients affected by essential thrombocythemia (ET) and primary myelofibrosis (PMF) [1, 2]. Several molecular assays have been developed to detect the most frequent *CALR*^{mut} (type 1 consisting of a 52-bp deletion, and type 2 of a 5-bp insertion) [3, 4]. All these techniques are useful for identifying *CALR*^{mut} at the diagnosis, but they are not suitable for minimal residual disease (MRD) monitoring, since the maximum sensitivity is 1 %. The droplet digital PCR (ddPCR) technology is a third-generation PCR method that started to be used in hematological malignancies [5–7]. We describe a ddPCR assay with a sensitivity of 0.01 % developed for the absolute quantification of *CALR* type 1 and 2 mutations and analyze a cohort of 57 *JAK2V617F*-negative myeloproliferative neoplasm patients. ddPCR experiments were performed using the QX-200 instrument (BioRad) and specific primers and probes were designed for both type 1 and type 2 mutations (see Supplementary Files). *CALR*^{mut} load in each sample was expressed as fractional abundance (FA, mutant allele/mutant allele + wild-type allele). The *CALR*^{mut} allelic burden resulted heterogeneous in both ET (min.13.8 %–max. 51 %) and PMF (min. 34.5 %–max. 51.3 %) patients. We show that the median *CALR*^{mut} allelic burden at diagnosis was significantly higher in PMF patients as compared to ET case (47.9 vs 43.8 %, $p = 0.008$) whereas no significant difference was observed between the type 1 and 2 mutations (Fig. 1a). Moreover, no relationship between the gene mutation type and the *CALR*^{mut} amount was observed within each group of ET and PMF patients. In our ET series, there were 14 (29.7 %) patients with a very low FA, <30 %; this group was not statistically different in terms of hemoglobin, white blood cells and platelet counts, age, sex, thrombosis and/or hemorrhage, and *CALR*^{mut} type compared to those with FA >30 %. The PMF group included ten patients, too few for any type of statistical considerations.

Sequential evaluations by ddPCR experiments were performed in three patients to monitor the *CALR*^{mut} load during treatment. *CALR*^{mut} load at diagnosis was 15.8 and 48 % in two ET patients. The former patient was treated with interferon-α (IFN-α) and after 5 years from diagnosis the FA was 7.7 %. The latter was also treated with IFN-α and after 2 years from diagnosis, the *CALR*^{mut} load was 14.7 %. Both patients had stable disease and a well-controlled platelet count. A 44-year-old man at PMF diagnosis showed a FA of 49.7 %; 8 years later, we observed a leukemic transformation. At the time of the AML evolution, the *CALR*^{mut} load was 0 %; this finding was also confirmed by PCR qualitative analysis. The patient underwent induction chemotherapy, achieving complete remission, then allogeneic bone marrow transplantation (ABMT) from a HLA-matched related donor. Two months later, the FA observed by ddPCR analysis was 0.01 %; 7 months after, the ABMT and AML relapsed and at this time, the *CALR*^{mut} load was 13.5 % (Fig. 1b, c).

Although the importance of the CALR allelic burden determination has not yet been defined at the disease onset, the utility of and need for a sensitive method, like our ddPCR assay, are unquestionable for the purposes of MRD monitoring [8–10].

Electronic supplementary material The online version of this article (doi:10.1007/s00277-016-2739-2) contains supplementary material, which is available to authorized users.

✉ Francesco Albano
francesco.albano@uniba.it

[1] Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, P.zza G. Cesare, 11, 70124 Bari, Italy



Fig. 1 **a** Distribution of *CALR* type 1- and 2-mutated copies determined by ddPCR and expressed in FA in 57 MPN patients. The median of the $CALR^{mut}$ allelic burden at diagnosis resulted to be 43.8 % in ET patients and 47.9 % in PMF, showing a statistically significant difference ($p = 0.008$). Each *dot* represents a patient. The *lines* indicate the median for each group. **b** Assessment of *CALR* mutation load by ddPCR in a PMF patient receiving ABMT. *CALR* mutation was not revealed at the time of AML evolution, whereas a low positivity (FA 0.01 %) was detected 2 months after ABMT and five months before hematological relapse. **c** 1-D plot showing each droplet corresponding to *CALR* mutations plotted on the graph of fluorescence intensity versus droplet number. All positive droplets are indicated in *blue*, whereas negative droplets are indicated in *gray*

Acknowledgments The authors would like to thank Ms. MVC Pragnell, B.A. for language revision of the manuscript. This work was supported by "Fondazione Cassa di Risparmio di Puglia."

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All procedures performed in this study were in accordance with the local Ethical Committee (Comitato Etico Indipendente Locale, Azienda Ospedaliera "Ospedale Policlinico Consorziale" di Bari, Regione Puglia) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study.

References

1. Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391–2405
2. Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379–2390
3. Jones AV, Ward D, Lyon M et al (2015) Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. Leuk Res 39:82–87
4. Chi J, Manoloukos M, Pierides C et al (2015) Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring. Ann Hematol 94:399–408
5. Albano F, Zagaria A, Anelli L et al (2015) Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia. Oncotarget 6:13269–13277
6. Drandi D, Kubiczkova-Besse L, Ferrero S et al (2015) Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR. J Mol Diagn 17:652–660
7. Zagaria A, Anelli L, Coccaro N et al (2015) BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR. Virchows Arch 467: 357–363
8. Mansier O, Migeon M, Saint-Lézer A et al (2016) Quantification of the mutant CALR allelic burden by digital PCR: application to minimal residual disease evaluation after bone marrow transplantation. J Mol Diagn 18:68–74
9. Badbaran A, Fehse B, Christopeit M et al (2016) Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation. Bone Marrow Transplant 51(6):872–873
10. Cassinat B, Verger E, Kiladjian JJ (2014) Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med 371: 188–189